Juli R Bago
Overview
Explore the profile of Juli R Bago including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
619
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Buckley A, Hagler S, Lettry V, Bago J, Maingi S, Khagi S, et al.
Mol Ther
. 2020 May;
28(7):1614-1627.
PMID: 32402245
The conversion of human fibroblasts into personalized induced neural stem cells (iNSCs) that actively seek out tumors and deliver cytotoxic agents is a highly promising approach for treating various types...
12.
Haney M, Zhao Y, Jin Y, Li S, Bago J, Klyachko N, et al.
J Neuroimmune Pharmacol
. 2019 Nov;
15(3):487-500.
PMID: 31722094
Efficient targeted delivery of anticancer agents to TNBC cells remains one of the greatest challenges to developing therapies. The lack of tumor-specific markers, aggressive nature of the tumor, and unique...
13.
Suryaprakash S, Lao Y, Cho H, Li M, Ji H, Shao D, et al.
Nano Lett
. 2019 Feb;
19(3):1701-1705.
PMID: 30773888
Mesenchymal stem cell (MSC) has been increasingly applied to cancer therapy because of its tumor-tropic capability. However, short retention at target tissue and limited payload option hinder the progress of...
14.
Sheets K, Bago J, Paulk I, Hingtgen S
J Vis Exp
. 2018 Jul;
(137).
PMID: 30059037
Glioblastoma (GBM), the most common and aggressive primary brain cancer, carries a life expectancy of 12-15 months. The short life expectancy is due in part to the inability of the...
15.
Sheets K, Bago J, Hingtgen S
Methods Mol Biol
. 2018 Jul;
1831:49-58.
PMID: 30051424
Engineered stem cells have recently entered clinical trials as therapeutic agents for treating glioblastoma foci that remain after primary brain tumor resection. However, efficient delivery of anti-cancer mesenchymal stem cells...
16.
Okolie O, Irvin D, Bago J, Sheets K, Satterlee A, Carey-Ewend A, et al.
PLoS One
. 2018 Jul;
13(7):e0198596.
PMID: 29990322
Background: Cytotoxic neural stem cells (NSCs) have emerged as a promising treatment for Medulloblastoma (MB), the most common malignant primary pediatric brain tumor. The lack of accurate pre-clinical models incorporating...
17.
Bago J, Okolie O, Dumitru R, Ewend M, Parker J, Vander Werff R, et al.
Sci Transl Med
. 2017 Feb;
9(375).
PMID: 28148846
Engineered neural stem cells (NSCs) are a promising approach to treating glioblastoma (GBM). The ideal NSC drug carrier for clinical use should be easily isolated and autologous to avoid immune...
18.
Okolie O, Bago J, Schmid R, Irvin D, Bash R, Miller C, et al.
Neuro Oncol
. 2016 Jun;
18(12):1622-1633.
PMID: 27298311
Background: Surgical resection is a universal component of glioma therapy. Little is known about the postoperative microenvironment due to limited preclinical models. Thus, we sought to develop a glioma resection...
19.
Bago J, Pegna G, Okolie O, Mohiti-Asli M, Loboa E, Hingtgen S
Biomaterials
. 2016 Mar;
90:116-25.
PMID: 27016620
Engineered stem cell (SC)-based therapy holds enormous promise for treating the incurable brain cancer glioblastoma (GBM). Retaining the cytotoxic SCs in the surgical cavity after GBM resection is one of...
20.
Bago J, Alfonso-Pecchio A, Okolie O, Dumitru R, Rinkenbaugh A, Baldwin A, et al.
Nat Commun
. 2016 Feb;
7:10593.
PMID: 26830441
Transdifferentiation (TD) is a recent advancement in somatic cell reprogramming. The direct conversion of TD eliminates the pluripotent intermediate state to create cells that are ideal for personalized cell therapy....